In addition, patients eligible for neoadjuvant chemotherapy in the early-stage disease setting might face several additional challenges, such as the impact of high-quality surgery on outcomes, the role of pathological complete response as a surrogate endpoint, and other cancer-related characteristics of HER2 low profile that might still be not well characterized [11]. Here, ERBB2 is linked to cancer.